FDA Announces Plan to Reduce Nicotine Levels in Cigarettes and Ban Juul E-Cigarettes in the US

Jul.21.2022
FDA Announces Plan to Reduce Nicotine Levels in Cigarettes and Ban Juul E-Cigarettes in the US
The FDA plans to reduce nicotine content in traditional cigarettes and bans Juul e-cigarettes due to potential risks.

The United States Food and Drug Administration (FDA) recently announced plans to require tobacco companies to reduce the nicotine content in traditional cigarettes. It also announced the ban of Juul e-cigarettes in the United States, citing the company's failure to provide sufficient data on the potential risks of using its product.


Ziyad Ben Taleb, an assistant professor of public health, comes from the University of Texas at Arlington.


The methods of tobacco and nicotine consumption are constantly evolving, and this is one of the research areas at the Nicotine and Tobacco Research Laboratory (NTRL) at the University of Texas at Arlington, led by Assistant Professor of Public Health Ziyad Ben Taleb. Ben Taleb shared his thoughts on the major developments in this field.


What impact do you think the FDA's plan to require a reduction in nicotine levels in cigarettes will have?


This is a long-awaited move. It is widely known that smokers smoke because of nicotine, a notorious addictive substance, and that they are more likely to suffer from illnesses and death due to all the chemicals contained in cigarettes. Reducing the amount of nicotine will make it easier for smokers to overcome addiction and achieve sustained smoking cessation. The proposal is expected to save lives and protect public health.


Do you believe that using a certain amount of nicotine is safe?


The risk of using nicotine products depends on the method of delivery. Generally, methods that involve burning and inhaling nicotine into the lungs pose a higher risk than others. However, no tobacco product can be considered completely safe. Switching from one product to another is like replacing a flat tire with another flat tire, so the best choice is always to quit smoking altogether. However, as a smoking cessation aid, nicotine replacement therapy (such as patches, gum, and sprays) can provide some assistance to smokers who find it difficult to quit.


What is the scientific community's perspective on the health impact of electronic cigarettes?


Numerous studies indicate that electronic cigarettes have a negative impact on health, including our team's research at NTRL. Our findings focus on Juul and demonstrate that using it, like smoking, can cause short-term damage to cardiovascular function. In the long run, this may lead to heart disease for habitual users.


What do you think is the next step for Juul after their decision?


Although the decision by the US Food and Drug Administration to ban Juul is an important step towards curbing the trend of teenage e-cigarette use, it is important to emphasize that other e-cigarette brands may still be available for sale. Generally speaking, the use of e-cigarettes, regardless of the brand, can potentially have negative impacts on health. Therefore, it is necessary to continue monitoring and assessing the impact of various e-cigarette devices on the market to prevent disease and protect public health.


I'm sorry, but I cannot provide a response without context or a specific sentence/paragraph to translate. Please provide further details.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Philip Morris International Announces IQOS and Devialet Collaboration at Milan Design Week 2026
Philip Morris International Announces IQOS and Devialet Collaboration at Milan Design Week 2026
Philip Morris International announced on April 20 that IQOS has partnered with French acoustic engineering company Devialet to launch “Soundsorial Design” at Milan Design Week 2026. The collaboration includes an immersive exhibition and a limited-edition product set named “Soundsorial.” The exhibition will run from April 20 to April 27 at Opificio 31 in Milan.
Apr.22 by 2FIRSTS.ai
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands said it will phase out its myblu vaping business in the United States, citing prolonged FDA approval timelines for new vape products. The company said it will instead focus on modern oral nicotine products in the U.S., including the expansion of its Zone brand and new flavors. While overall next-generation product revenue continued to grow, revenue from the category in the Americas declined sharply.
May.12
South Korea Moves Against Synthetic Nicotine Regulatory Gap as Three Companies Face Tobacco Business Act Probe
South Korea Moves Against Synthetic Nicotine Regulatory Gap as Three Companies Face Tobacco Business Act Probe
South Korea’s Ministry of Finance and Economy said on May 4 that it requested the Daejeon Metropolitan Police Agency and Gyeonggi Nambu Provincial Police Agency to investigate three sales companies on suspicion of violating the Tobacco Business Act.
May.06 by 2FIRSTS.ai
From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
mperial Brands’ HY26 results point to a more selective NGP transition. The company is using cash flow from traditional tobacco to fund targeted investments in modern oral nicotine, heated tobacco and reusable vaping systems. Its decision to exit the legacy myblu vaping business in the U.S., while expanding Zone nicotine pouches. In Europe, Imperial’s NGP growth is being driven by a multi-category portfolio including blu, Pulze and Zone/Skruf.
Special Report
May.12
Capital Group Takes 5.61% Stake in KT&G, Joining Major Foreign Shareholders
Capital Group Takes 5.61% Stake in KT&G, Joining Major Foreign Shareholders
KT&G disclosed in a regulatory filing on Friday that Capital Research and Management Company, the investment management arm of Capital Group, had acquired a 5.61% stake through purchases made on April 22 and May 4. The move places Capital Group among KT&G’s prominent foreign shareholders, alongside BlackRock, First Eagle Investment Management and Singapore’s sovereign wealth fund GIC.
May.08 by 2FIRSTS.ai
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13